- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.09. | Regeneron reports phase 3 win in ultrarare disease, bouncing back to spark race to FDA | ||
| 17.09. | Lilly rounds out oral GLP-1 weight loss data, posts semaglutide-topping results in diabetes | ||
| 17.09. | Why Sanofi's R&D chief is 'pretty pragmatic' about a 'mixed' year of clinical development | ||
| 17.09. | Roivant reports phase 3 autoimmune win for ex-Pfizer asset | ||
| 17.09. | Innate to lose 30% of workforce, including CSO, in focus on 'highest-value assets' | ||
| 17.09. | Pharma tells Scotland how to court investment amid UK life sciences turmoil | ||
| 16.09. | Pharma execs cite 'challenging' environment during grilling by UK lawmakers over R&D pullback | ||
| 16.09. | Genmab discards clinical ADC picked up in last year's $1.8B ProfoundBio buy | ||
| 16.09. | Apollo's $15M bet on IL-18 antibody pays off with phase 2 eczema win | ||
| 16.09. | Areteia posts phase 3 asthma win for potential oral rival to biologic blockbusters | ||
| 16.09. | Novo sees amylin drug underperform Wegovy in phase 3, but pushes ahead with development | ||
| 16.09. | CSL pays $117M for option on phase 3-ready blood clotting specialist VarmX | ||
| 15.09. | Flagship's Lila Sciences lands $235M to expand AI-powered autonomous research labs | ||
| 15.09. | CatalYm taps 4 industry vets, lets go of 3 leaders in C-suite change up | ||
| 15.09. | Sanofi becomes latest pharma to hold fire on UK R&D investments as funding fallout continues | ||
| 15.09. | aTyr flunks phase 3 lung disease trial, deflating stock, but still plans talks with FDA | ||
| 15.09. | Novartis assembles 2nd molecular glue deal with Monte Rosa, this one worth up to $5.7B | ||
| 12.09. | AstraZeneca pauses $271M expansion in UK-the latest big pharma to buck Britain | ||
| 12.09. | Eli Lilly reconsiders UK biotech incubator, pauses buildout: reports | ||
| 12.09. | Galimedix starts phase 2 fundraise after oral Alzheimer's candidate clears safety test | ||
| 11.09. | Arrowhead battles Ionis over patent dispute tied to RNAi candidate that could rival Tryngolza | ||
| 11.09. | FibroGen pays SEC $1.2M over allegations former exec 'reverse engineered' roxadustat data | ||
| 11.09. | Capsida pauses phase 1 gene therapy trial after child dies | ||
| 11.09. | LB Pharmaceuticals upsizes IPO to $285M in first biotech listing in months | ||
| 10.09. | Merck executes its own Brexit, moving all R&D operations out of UK |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .